KU Leuven

Postdoctoral project on cancer therapy via nanomedicine, engineered cells and preclinical imaging

2024-11-15 (Europe/Brussels)
Tallenna työpaikka

Tietoja työnantajasta

KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.

Käy työnantajan sivulla

The work to be performed is linked to the research group "NanoHealth and Optical Imaging" at the Faculty of Medicine (KU Leuven, Belgium). This research group is part of the Translational Cell and Tissue Research Unit and is further heading the Centre for Multimodal Oncology Research (C-More). The latter houses a wide range of non-invasive imaging modalities, which the applicant will join. Our team has an excellent international reputation in nanomedicine and optical imaging. We also often work together with other research groups at the KULeuven to assist them with imaging techniques.

The field of nanomedicine is receiving increasing attention and has enormous potential for a plethora of pathological conditions, including cancer. One of the main advantages of nanomaterials is the ability to combine multiple modalities in one platform, allowing the nanomaterials to be used simultaneously for diagnostic and therapeutic applications and to use multiple therapeutic options simultaneously. The main bottlenecks hindering the full use of nanomaterials for biomedical purposes is the need for a higher level of selectivity in terms of targeted delivery of the nanomaterials to the target cells, along with the development of new, alternative therapeutic options. These topics are central to the research group. To answer these questions, multidisciplinary research is highly regarded, in which we make extensive use of non-invasive imaging (optical imaging and soon magnetic particle imaging) to investigate the biodistribution and functionality of the nanoformulations.

Website unit

Responsibilities

Main responsibilities:

  • Design, development and characterization of nanoformulations with genetic cargo (mRNA, siRNA, pDNA).
  • The culture, evaluation and validation of engineered cell types (CAR-NK and CAR-T).
  • The applicant will work on synthesis of nanoformulations. Microfluidic systems (e.g. Ignite system from Precision Nanomedicine) are available in-house to assist.
  • The applicant will work on biodistribution and targeted delivery of either the engineered cells or nanoformulations using in vitro (cell culture) and in vivo (mouse models) systems.
  • The applicant will propose and design novel targets and/or methods for improving targeted delivery of their therapeutic agents
  • The applicant will contribute to teaching the techniques to PhD students and follow-up on different students.

Profile

The applicant has:
 
  • A PhD (recently completed) linked to biology, medical sciences, pharmaceutical sciences or the like.
  • The applicant has experience in cell culture and animal handling and is certified to perform animal experiments.
  • Experience with synthesis and characterization of solid lipid nanoparticles, poly(beta-amino esters) and/or chitosan nanoparticles for siRNA, mRNA or pDNA encapsulation is a plus.
  • Experience with generating and evaluating CAR-T or CAR-NK cells is a plus.
  • Experience with performing in vitro and in vivo tests related to toxicity, encapsulation efficacy and therapeutic efficacy of loaded nanoparticles is a plus
  • Any experience with biomimetics for encapsulation of nanocomplexes with biological membranes is a plus
  • Any experience with preclinical studies (biodistribution, therapeutic efficacy) is a plus.
  • International applicants are a plus, but not a requirement.
  • Applicants must be enthusiastic, dynamic, reliable and accurate, willing to incorporate previously learned techniques into new approaches.
  • The applicant is a good team player, who likes to be closely supervised and who can also work independently.
  • Must have a great sense of responsibility and good organizational skills.
  • Applicants must be able to communicate well in English.  

Offer

Funding is available to support the candidate, where the first year will be seen as an evaluation year. Upon a positive evaluation, the contract can be extended for another 2 years, or, depending on the specific conditions of the applicant, they can submit an application for an external fellowship for 3 years. For this we will guide the candidate in submitting the application. 
 
The applicant's knowledge and experience will grow with a multidisciplinary team at KULeuven and there will be ample opportunities to learn from and interact with experienced researchers in various associated research domains.

Interested?

For more information please contact Prof. dr. Stefaan Soenen, tel.: +32 16 33 00 34, mail: s.soenen@kuleuven.be.

KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.

Lisätietoa työpaikasta

Otsikko
Postdoctoral project on cancer therapy via nanomedicine, engineered cells and preclinical imaging
Työnantaja
Sijainti
Oude Markt 13 Leuven, Belgia
Julkaistu
2024-10-26
Viimeinen hakupäivä
2024-11-15 23:59 (Europe/Brussels)
2024-11-15 23:59 (CET)
Työpaikan tyyppi
Tallenna työpaikka

Lisää työpaikkoja tältä työnantajalta